# Study Guide: 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis This study guide provides a synthesis of the 2021 American College of Rheumatology (ACR) guidelines for the pharmacologic management of Rheumatoid Arthritis (RA). It covers treatment strategies for various patient populations, medication administration, and the principles of the "treat-to-target" approach. --- ## I. Key Concepts and Treatment Principles ### 1. The Role of Methotrexate (MTX) Methotrexate remains the "anchor" medication for RA treatment. The guidelines emphasize maximizing its use before switching to or adding more expensive or complex therapies. * **Initial Therapy:** For DMARD-naive patients with moderate-to-high disease activity, MTX monotherapy is strongly recommended over hydroxychloroquine, sulfasalazine, and biologic or targeted synthetic DMARDs (bDMARDs/tsDMARDs). * **Dosing and Administration:** * **Route:** Oral MTX is conditionally recommended over subcutaneous (SQ) MTX for initiation. However, switching to SQ or split dosing is recommended for patients experiencing side effects or failing to reach targets on oral doses. * **Titration:** Clinicians should aim to titrate to a weekly dose of at least 15 mg within 4 to 6 weeks. * **Pulmonary and Hepatic Considerations:** MTX is conditionally recommended for patients with stable, mild airway/parenchymal lung disease and for those with Nonalcoholic Fatty Liver Disease (NAFLD) provided they have normal liver enzymes and no evidence of advanced fibrosis. ### 2. Glucocorticoid Stewardship A major shift in the 2021 guideline is the strong stance against prolonged glucocorticoid use due to significant toxicity (e.g., osteoporosis, cardiovascular disease, and infection risk). * **Short-term (<3 months):** Conditionally recommended against systematic use, though acknowledged as often necessary for symptom relief before DMARDs take effect. * **Long-term (≥3 months):** Strongly recommended against. * **Tapering:** In patients with Nontuberculous Mycobacterial (NTM) lung disease, clinicians should use the lowest possible dose or discontinue steroids entirely. ### 3. Treat-to-Target (TTT) and Tapering Treat-to-target is a systematic approach involving frequent monitoring and treatment adjustment to reach a predefined goal. * **Priority:** TTT is strongly recommended for bDMARD/tsDMARD-naive patients. * **Goals:** Low disease activity (LDA) is the preferred initial goal over remission, as remission may be dishearteningly difficult for some patients to achieve initially. * **Tapering Conditions:** Patients must be at their target (LDA or remission) for at least **6 months** before tapering is considered. * **Tapering Order:** Dose reduction is preferred over gradual discontinuation, which is preferred over abrupt discontinuation. Patients should always maintain a therapeutic dose of at least one DMARD. ### 4. Management of High-Risk Populations | Condition | Recommendation Summary | | :--- | :--- | | **Heart Failure (NYHA III/IV)** | Avoid TNF inhibitors; prefer non-TNF inhibitor bDMARDs or tsDMARDs. | | **Lymphoproliferative Disorder** | Rituximab is preferred over other DMARDs. | | **Hepatitis B** | Prophylactic antivirals are strongly recommended for those who are core antibody (+) and surface antigen (+). | | **Previous Serious Infection** | Within 12 months of infection, prefer adding csDMARDs over bDMARDs/tsDMARDs. | | **NTM Lung Disease** | Prefer csDMARDs over biologics; if a biologic is needed, Abatacept is preferred. | --- ## II. Short-Answer Practice Quiz **1. Why is Methotrexate strongly recommended over bDMARD or tsDMARD monotherapy in DMARD-naive patients?** *Answer:* MTX has established long-term safety and efficacy, lower cost, and its status as an "anchor" for combination therapy. Additionally, several bDMARDs/tsDMARDs are not FDA-approved for csDMARD-naive patients. **2. Under what circumstances should a clinician switch from oral to subcutaneous Methotrexate?** *Answer:* When a patient is not reaching their disease activity target on oral MTX or when they are experiencing intolerance/side effects with the oral formulation. **3. What is the recommended minimum duration of stable disease activity before a patient can begin tapering DMARDs?** *Answer:* Patients should be at their target (low disease activity or remission) for at least 6 months. **4. For a patient with NYHA Class III or IV heart failure, which class of bDMARDs should be avoided?** *Answer:* Tumor Necrosis Factor (TNF) inhibitors should be avoided, as they have been linked to worsening heart failure. **5. What is the ACR's stance on "triple therapy" versus adding a biologic for patients failing MTX monotherapy?** *Answer:* The guideline conditionally recommends adding a bDMARD or tsDMARD over triple therapy. This is based on patient preferences for a more rapid response and the higher "persistence" (likelihood of staying on the drug) of biologics compared to triple therapy. **6. Which medication is preferred for a patient with a history of a lymphoproliferative disorder for which that specific drug is an approved treatment?** *Answer:* Rituximab. --- ## III. Essay Prompts for Deeper Exploration 1. **The Evolution of RA Management:** Compare the 2015 and 2021 guidelines regarding the categorization of disease. Discuss why the 2021 update moved away from "early" vs. "established" RA subgroups in favor of focusing on current disease activity and comorbidities. 2. **The Glucocorticoid Paradox:** While glucocorticoids provide rapid symptomatic relief, the 2021 guidelines strongly advise against their long-term use. Analyze the risks associated with prolonged steroid therapy and the clinical challenges of successfully tapering patients off these medications. 3. **Shared Decision-Making in Tapering:** The voting panel (clinicians) and the patient panel had different priorities regarding DMARD tapering. Explore these differences (e.g., patient desire to be "drug-free" vs. clinician fear of "flare") and explain how shared decision-making bridges these perspectives. 4. **Safety Signals and tsDMARDs:** Discuss the impact of the 2021 FDA Drug Safety Alert regarding JAK inhibitors (tofacitinib) on the RA treatment landscape, particularly concerning cardiovascular events and malignancies. --- ## IV. Glossary of Important Terms * **bDMARD (Biologic Disease-Modifying Antirheumatic Drug):** Large-molecule drugs produced by living cells, including TNF inhibitors (e.g., adalimumab, etanercept), T-cell inhibitors (abatacept), IL-6 inhibitors (tocilizumab), and anti-CD20 antibodies (rituximab). * **csDMARD (Conventional Synthetic DMARD):** Small-molecule traditional RA drugs, including methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide. * **Dose Reduction:** Lowering the dose of a medication or increasing the interval between doses (e.g., moving from once a week to once every two weeks). * **Gradual Discontinuation:** The process of slowly lowering the dose of a DMARD until it is eventually stopped completely. * **GRADE Approach:** A systematic method for rating the certainty of evidence and the strength of recommendations. * **PICO Questions:** A framework used to develop clinical questions (Population, Intervention, Comparator, and Outcomes). * **Targeted Synthetic DMARD (tsDMARD):** Small-molecule drugs that target specific pathways within immune cells, specifically JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib). * **Treat-to-Target (TTT):** A strategy of treating a patient aggressively to reach a specific, measurable goal (low disease activity or remission) through frequent monitoring. * **Triple Therapy:** A specific combination of three csDMARDs: typically hydroxychloroquine, sulfasalazine, and either methotrexate or leflunomide.